

A003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Applicants : Jeffrey Browning and Yves Chicheportiche
Application No. : 09/245,198 Confirmation No.: 4642
Filed : February 5, 1999
For : A TUMOR NECROSIS FACTOR RELATED LIGAND
Examiner : Richard Schnizer
Group Art Unit : 1635

New York, New York 10020
April 19, 2004


Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is a Supplemental Information Disclosure Statement, Form PTO-1449 and references cited therein, in the above-identified application. This Supplemental Information Disclosure Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311. In accordance with 37 C.F.R. § 1.97, this Statement is accompanied by the fee as set forth in 37 C.F.R. § 1.17(p). Accordingly, a check in the amount of \$180.00 is enclosed.


The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Supplemental Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



Margaret A. Pierri (Reg. No. 30,709)
Attorney for Applicants
Connie Wong (Limited Recognition)
Agent for Applicants

FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax: (212) 596-9090

A003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Richard Schnizer
Group Art Unit : 1635
Applicants : Jeffrey Browning and Yves Chicheportiche
Application No. : 09/245,198 Confirmation No. : 4642
Filing Date : February 5, 1999
For : A TUMOR NECROSIS FACTOR RELATED LIGAND

New York, New York
April 19, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following documents, copies of which are submitted herewith:

OTHER DOCUMENTS

Marra et al., "The WashU-HHMI Mouse EST project. my18d09.r1
Barstead mouse heart MPLRB3 Mus musculus cDNA clone 696209 (5')" EMBL
DATABASE ENTRY MMAA221610, ACCESSION NO. AA221610, 15 February
1997, XP002049707.

Nakaya et al., "Regulation of Asialoglycoprotein Receptor Synthesis by Inflammation-Related Cytokines in HepG2 Cells," *J. Gastroenterol.* 29:24-30 (1994).

For the Examiner's convenience, applicants have enclosed a completed Form PTO-1449, listing these documents.


Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the course of examination of this application and (2) printed on any patent issuing from this application. Applicants request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next official communication.

This Supplemental Information Disclosure Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

In accordance with 37 C.F.R. § 1.97, this Statement is accompanied by the fee as set forth in 37 C.F.R. § 1.17(p). Accordingly, a check in the amount of \$180.00 is enclosed.

The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Supplemental Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this Statement is transmitted herewith.

Respectfully submitted,

A handwritten signature in cursive script that reads "Connie Wong". The signature is written in black ink and is positioned above a horizontal line.

Margaret A. Pierri (Reg. No. 30,709)

Attorney for Applicants

Connie Wong (Limited Recognition)

Agent for Applicants

c/o FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020

Tel.: (212) 596-9000

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
A003APPLICATION NO.
09/245,198INFORMATION DISCLOSURE
STATEMENT BY APPLICANTSAPPLICANTS
Jeffrey Browning et al.CONFIRMATION
NO.
4642FILING DATE
February 5, 1999GROUP
1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT PUBLICATION DOCUMENTS

EXAMINER INITIAL	PUBLICATION NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Marra et al., "The WashU-HHMI Mouse EST project. my18d09.r1 Barstead mouse heart MPLRB3 Mus musculus cDNA clone 696209 (5')" EMBL DATABASE ENTRY MMAA221610, ACCESSION NO. AA221610, 15 February 1997, XP002049707.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

APPLICATION NO.
09/245,198

**CONFIRMATION
NO.
4642**

GROUP
1635

[illegible]

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.